Sutro Biopharma, Inc.
STROHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeSutro Biopharma, Inc. operates as an oncology company. The company carries a $491.0M market cap, placing it firmly in the small-cap category. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Market Cap
$491.0M
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
-4.31
EPS (TTM)
$-16.35
EPS (Fwd)
$-6.87
ROE
—
ROA
-23.4%
Cash
$141.4M
Total Debt
$15.7M
Free CF
-$112.4M
52W Change
229.2%
Annual Financials
Cash vs Debt
Sutro Biopharma, Inc. holds $141.4M in cash against $15.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$112.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $67.8M (2022) to $102.5M (2025), reflecting a 51% increase over the period.
Sutro Biopharma, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, STRO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing STRO.